Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.313 USD | +5.23% | +7.04% | -30.19% |
May. 09 | GoHealth, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Transcript : GoHealth, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.53% | 88.03M | D+ | ||
+0.19% | 63.7B | C | ||
+14.54% | 56.03B | B- | ||
+5.53% | 25.88B | C+ | ||
+26.79% | 25.63B | C | ||
+23.57% | 9.46B | - | ||
+25.52% | 6.46B | - | ||
-3.44% | 4.19B | B | ||
+43.01% | 2.25B | C- | ||
+6.16% | 2.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GOCO Stock
- Ratings GoHealth, Inc.